FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer

Trial

HERIZON-BTC-01

Drug

Ziihera (zanidatamab-hrii) · Anti-HER2 bispecific antibody

Condition

Gastrointestinal